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Background: Peoplewith schizophrenia are at signiﬁcantly greater risk of cardiovascular disease-relatedmortality.
We set out to determine if people with and without schizophrenia who undergo coronary artery catheterization
differ with respect to coronary anatomy, coronary artery disease management, or outcome.
Methods and results: This study used provincial administrative data and a clinical registry that included all indi-
vidualswho undergo coronary catheterization inAlberta, Canada. Individualswith schizophreniawere identiﬁed
in hospital discharge data using ICD-9 codes. We identiﬁed 271 Albertans with a hospital discharge diagnosis
of schizophrenia and a subsequent coronary catheterization and were matched with 1083 controls without
schizophrenia that had undergone a coronary catheterization. Extent of coronary disease was assessed using 1)
left ventricular ejection fraction; 2) the Duke Jeopardy Score (a valid measure of myocardium at risk for ischemic
injury); and 3) a categorical assessment of coronary anatomy risk. Peoplewith schizophreniawere less likely to be
categorized as high risk on the Duke coronary index (p b .005) andmore likely to be categorized as having a nor-
mal coronary anatomy (p b .05). Signiﬁcant differences in mortality were found among those with and without
schizophrenia both before and after adjustment for clinical differences.
Conclusions: Our results suggest that people with schizophrenia have less severe coronary atherosclerosis, and are
less likely to receive revascularization. Despite less severe coronary atherosclerosis, individualswith schizophrenia
had a signiﬁcantly highermortality following catheterization. Interventions to increase therapeutic adherence and
clinical follow up of patients with mental illness may improve health outcomes.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Schizophrenia is a potentially debilitating chronicmental illness that
affects approximately 1% of the Canadian population [1]. Schizophrenia
also confers signiﬁcant risk for physical illness and prematuremortality.
Individuals with schizophrenia are known to have a 20% reduction in
life expectancy and this increased mortality rate has been persistent
over time despite major advances in psychiatric care [2].
Persons with schizophrenia are at increased risk for cardiovascular
disease (CVD) — related mortality compared to those without schizo-
phrenia [3,4]. This increase in risk has been attributed to a number ofity of Calgary, TRW 3E21, 3280
220 8867; fax: +403 210 8113.
(D.M. Rabi).
eliability and freedom from bias
and Ltd. This is an open access articlefactors including a higher burden of comorbid illness, a high prevalence
of smoking and sedentary lifestyle, and the use of atypical antipsychotic
agents (AAPs), a class of medications which are known to increase the
risk of metabolic syndrome, obesity and type 2 diabetes [5–7].
It has been suggested that inequitable access to caremay be another
mediating mechanism underlying the association between schizophre-
nia and poor CVD outcomes [8]. Previous research has shown that peo-
plewith schizophrenia are less likely to undergo cardiac catheterization,
percutaneous coronary intervention (PCI), and coronary artery bypass
grafting (CABG) relative to those without schizophrenia [9–12]. Factors
such as cardiac surgeon selection bias [13], socio-economic barriers
[14], and informed consent issues [6] have been postulated as possible
causes for this discrepancy. However, to the best of our knowledge,
the possibility of these treatment differences being related to underly-
ing differences in the anatomy of coronary disease has not been
explored. It is unclear whether this apparent discrepancy in treatment
may be explained by differences in coronary anatomy, such that personsunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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amenable to revascularization.
The objectives of this study were to: 1) ascertain the proportion of
people with and without schizophrenia who receive coronary revascu-
larization (PCI or CABG) following cardiac catheterization; 2) describe
the relationship between the clinical proﬁles and coronary anatomy of
those with and without schizophrenia; and 3) determine mortality
among persons with and without schizophrenia following coronary
catheterization.
2. Methods
2.1. Study cohort and data sources
This cohort study was performed using administrative health and
clinical registry data from the Alberta Health Services Discharge
Abstract Database (DAD) from Alberta Health and Wellness, and the
Alberta Provincial Project for Outcome Assessment in Coronary Heart
Disease (APPROACH) [15]. The DAD contains demographic and clinical
information for all patients discharged from any hospital using Interna-
tional Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM) and ICD-10-Canada (ICD-10_CA). APPROACH is an ongoing
prospective data collection initiative that has captured detailed clinical
information on all patients undergoing cardiac catheterization and
subsequent interventions in the province of Alberta, Canada since
1995 [6]. After data collection from the APPROACH database, a data
enhancement process veriﬁes patient comorbidities and maximizes
data completeness [7,8]. Lastly, we obtained information on mortality
for all patients through quarterly linkage to the Alberta Bureau of Vital
Statistics. Individuals in these datasets are linked using a unique lifetime
identiﬁer, the Personal Health Number (PHN).
2.2. Identiﬁcation of study cohort
People with schizophrenia (cases) were identiﬁed using the DAD.
Those who had a hospital discharge between March 14, 1995 and
December 31, 2009 with a diagnosis of schizophrenia (ICD-9 295;
ICD-10 F20) in any diagnostic ﬁeld were classiﬁed as having schizophre-
nia [16]. These people were then cross-referenced with the APPROACH
registry to identify those who underwent coronary revascularization.
They were then matched by age, sex, ﬁscal year, and indication for
coronary catheterization in a ratio of 1 case to 4 controls with people in
the APPROACH registry who had undergone coronary catheterization
but without a prior discharge diagnosis of schizophrenia. Excluded
from this study were people for whom the coronary catheterization pre-
ceded the ﬁrst recorded hospital discharge of schizophrenia, non-Alberta
residents, and people with incomplete comorbidity data.
2.3. Clinical and outcome variables
Using data fromAPPROACH, extent of coronary diseasewas assessed
using 3 different measures: 1) left ventricular ejection fraction (LVEF);
2) the Duke Jeopardy Score, which encompasses both the percentage
of stenosis in a coronary lesion and the volume of myocardium at risk
(the Duke Jeopardy Score has been validated in the APPROACH popula-
tion and has been shown to provide independent prognostic informa-
tion in people with ischemic heart disease) [9,10]; and 3) a categorical
assessment of coronary anatomy risk, with high risk anatomy deﬁned
as 3-vessel disease, left main disease, or 2-vessel disease involving
the proximal left anterior descending coronary artery per the Duke
Coronary Index.
2.3.1. Ethics approval
The Conjoint Health Research Ethics Boards of the University of
Calgary approved this study.3. Statistical methods
The baseline characteristicswere compared using chi-square, Fisher's
exact, or t-tests as appropriate. Treatment and revascularization within
one year following catheterization were compared between groups
using chi-square tests. Differences in survival were assessed using
Kaplan–Meier curves and Cox proportional hazard models. After ensur-
ing that the proportional hazard assumption was met, we evaluated
survival using the corrected group prognosis method, adjusted for
comorbidities, clinical characteristics and treatment [17]. We performed
a sensitivity analysis limited to people whose indication for catheteriza-
tion was acute myocardial infarction (AMI) (either ST-elevation or
nonST-elevation MI). All analyses were performed using SAS software
version 9.1 (SAS Institute Inc., Cary, NC, USA).4. Results
We identiﬁed 271 people with a hospital discharge diagnosis of
schizophrenia between March 14, 1995 and December 31, 2009 and a
subsequent coronary catheterization. These individuals were matched
with 1083 controls that had undergone a coronary catheterization but
had no hospital discharge record of schizophrenia. Clinical and demo-
graphic proﬁles of those with and without schizophrenia are presented
in Table 1. People with schizophrenia had a greater comorbid disease
burden than people without schizophrenia. A greater proportion of peo-
ple with schizophrenia than controls had cerebrovascular disease (8.9%
vs. 5.4%, p = 0.031), pulmonary disease (23.3% vs. 13.6%, p b 0.001),
congestive heart failure (21.4% vs. 13.4%, p b 0.001), renal disease
(7% vs. 3.3%, p = 0.006) and diabetes (25.5% vs. 20.1% p = 0.054) at
the time of catheterization. Additionally, a greater proportion of people
with schizophrenia were smokers (48% vs. 35.1%, p b 0.001).
No signiﬁcant differenceswere seen in cardiac event history, including
prior MI (32.5% vs. 30.4% p = 0.50), prior PCI (3.7% vs. 4.2% p = 0.73),
and prior CABG (1.9% vs. 2.8% p = 0.35).
Those with schizophrenia were less likely to have a LVEF, over 50%
relative to those without schizophrenia (53.1% vs. 61.1%, p = 0.021),
but were more likely to have an LVEF in the 20–34% class than those
without schizophrenia (8.9% vs. 5.0% p = 0.021) (Table 2). These
clinical differences were also found when the analysis was limited to
those with AMI.
In addition, people with schizophrenia were less likely to be
categorized as high risk on the Duke Coronary Index (18.8% vs.
25.6% p = 0.021) andmore likely to be categorized as having a normal
coronary anatomy (32.5% vs. 25.6% p = 0.021). When analysis was
restricted to those with AMI, such differences in clinical anatomy were
not seen. People presenting with AMI, irrespective of schizophrenia
status, appeared to have similar coronary anatomy.
Within one year of catheterization, a greater proportion of people
with schizophrenia were treated medically than those without schizo-
phrenia (53.1% vs. 45.2% p= 0.05) (Table 3). Those with schizophrenia
were treated less frequently with surgical interventions such as CABG
(11.4% vs. 15.1% p = 0.05) and PCI (35.4% vs. 39.8% p = 0.05). These
differences were attenuated but still persisted when the analysis was
restricted to those with AMI.
Signiﬁcantdifferences inmortalitywere foundamong thosewith and
without schizophrenia both before (crude hazard ratio [HR]: 2.19; 95% CI
1.68–2.85; p b 0.001) and after adjustment for clinical differences
(adjusted HR: 1.85; 95% CI 1.39–2.4; p b 0.001) (Table 4). Similarly, the
Kaplan Meier curve (Fig. 1), which displays survival up to 15 years
after catheterization shows a signiﬁcant decrease in survival among
those with schizophrenia. Cause of death data was available for 67 of
the people in the cohort (4.9%). Among this small sub-sample of people,
AMI was the most frequently reported cause of death and there were no
signiﬁcant differences in cause of death among those with or without
schizophrenia (Fig. 2).
Table 1
Characteristics of the study cohort.
Full cohort AMI only
N = 1354 N = 564
Controls Cases p-Value Controls Cases p-Value
N = 1083 N = 271 N = 451 N = 113
Demographics
Mean age in years (SD) 58.5 (11.8) 58.7 (11.8) (Matched) 59.3 (11.6) 59.3 (11.7) (Matched)
Age N75 years 104 (9.6) 26 (9.6) (Matched) 56 (12.4) 14 (12.4) (Matched)
Male 600 (55.4) 150 (55.4) (Matched) 264 (58.5) 66 (58.4) (Matched)
Dead 170 (15.7) 82 (30.3) b0.0001 71 (15.7) 35 (31.0) 0.0002
Burden of comorbid disease
Cerebrovascular disease 58 (5.4) 24 (8.9) 0.031 28 (6.2) 11 (9.7) 0.19
Pulmonary disease 147 (13.6) 63 (23.3) b0.0001 61 (13.5) 25 (22.1) 0.023
Congestive heart failure 145 (13.4) 58 (21.4) 0.001 47 (10.4) 25 (22.1) 0.0009
Liver/gastro-intestinal disease 73 (6.7) 23 (8.5) 0.32 25 (5.5) 8 (7.1) 0.53
Peripheral vascular disease 63 (5.8) 15 (5.5) 0.86 25 (5.5) 5 (4.4) 0.64
Renal disease (creatinine N 200 mmol/L) 36 (3.3) 19 (7.0) 0.006 13 (2.9) 9 (8.0) 0.025
Malignancy 30 (2.8) 5 (1.9) 0.39 9 (2.0) 2 (1.8) 0.75a
Hypertension 667 (61.6) 158 (58.3) 0.32 268 (59.4) 68 (60.2) 0.88
Hyperlipidemia 738 (68.1) 172 (63.5) 0.14 312 (69.2) 78 (69.0) 0.97
Dialysis 17 (1.6) 3 (1.1) 0.78a 4 (0.9) 0 0.59a
Diabetes 218 (20.1) 69 (25.5) 0.054 85 (18.9) 31 (27.4) 0.043
Current smoker 380 (35.1) 130 (48.0) b0.0001 190 (42.1) 64 (56.6) 0.006
Previous smoker 382 (35.3) 86 (31.7) 0.27 147 (32.6) 28 (24.8) 0.11
Prior lytic therapy 82 (7.6) 14 (5.2) 0.17 69 (15.3) 14 (12.4) 0.43
Cardiac history
Prior MIb 329 (30.4) 88 (32.5) 0.50 194 (43.0) 53 (46.9) 0.46
Prior PCIc 45 (4.2) 10 (3.7) 0.73 16 (3.6) 3 (2.7) 0.78a
Prior CABGd 31 (2.8) 5 (1.9) 0.35 10 (2.2) 3 (2.7) 0.73a
Indication for catheterization (Matched) (matched)
Stable angina 188 (17.4) 47 (17.3)
Myocardial infarction 451 (41.6) 113 (41.7) 451 (100.0) 113 (100.0)
Unstable angina 296 (27.3) 74 (27.3)
Other 148 (13.7) 37 (13.7)
a Fisher's exact test.
b Myocardial infarction.
c Percutaneous coronary intervention.
d Coronary artery bypass graft.
Table 2
Coronary function and anatomy.
Full cohort AMI only
N = 1354 N = 564
Controls Cases p-Value Controls Cases p-Value
N = 1083 N = 271 N = 451 N = 113
Left ventricular ejection fraction 0.021 0.006
N50% 662 (61.1) 144 (53.1) 242 (53.7) 46 (40.7)
35–50% 203 (18.7) 48 (17.7) 117 (25.9) 25 (22.1)
20–34% 54 (5.0) 24 (8.9) 22 (4.9) 14 (12.4)
b20% 12 (1.1) 1 (0.4) 3 (0.7) 0
Couldn't be done/not done 76 (7.0) 28 (10.3) 36 (8.0) 13 (11.5)
Unknown 76 (7.0) 26 (9.6) 31 (6.9) 15 (13.3)
Duke Jeopardy Score 0.73 0.34
0/12 361 (33.4) 105 (38.9) 70 (15.5) 17 (15.2)
2/12 279 (25.8) 66 (24.4) 170 (37.7) 40 (35.7)
4/12 100 (9.3) 24 (8.9) 47 (10.4) 17 (15.2)
6/12 142 (13.2) 30 (11.1) 79 (17.5) 15 (13.4)
8/12 81 (7.5) 17 (6.3) 37 (8.2) 11 (9.8)
10/12 59 (5.5) 16 (5.9) 21 (4.7) 9 (8.0)
12/12 58 (5.4) 12 (4.4) 27 (6.0) 3 (2.7)
Duke Coronary Index 0.07 0.13
Normal/b50% 277 (25.6) 88 (32.5) 39 (8.7) 10 (8.9)
Low riska 467 (43.1) 113 (41,7) 258 (57.8) 63 (55.8)
High riskb 277 (25.6) 51 (18.8) 138 (30.6) 32 (28.3)
Left mainc 54 (5.0) 17 (6.3) 16 (3.6) 6 (5.3)
Missing/not entered 8 (0.7) 2 (0.7) 0 2 (1.8)
a Duke Index 1–6 (1VD 50–75%, 1VD 95%, 2VD, 2 VD both 95%, 1VD 95% PLAD, 2VD 95% PLAD).
b Duke Index 7–11 (2VD 95% PLAD, 3VD, 3VD 1–95%, 3VD PLAD, 3VD 95% PLAD).
c Duke Index 12 or 13 (left main, severe left main).
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Table 3
Treatment and revascularization within one year of catheterization.
Full cohort AMI only
N = 1354 N = 564
Controls Cases p-Value Controls Cases p-Value
N = 1083 N = 271 N = 451 N = 113
Treatment within one year of catheterization 0.050 0.17
Medical management 489 (45.2) 144 (53.1) 109 (24.2) 37 (32.7)
CABGa 163 (15.1) 31 (11.4) 57 (12.6) 12 (10.6)
PCIb 431 (39.8) 96 (35.4) 285 (63.2) 64 (56.6)
Any revascularizationc within 1 year of index catheterization 594 (54.9) 127 (46.9) 0.019 342 (75.8) 76 (67.3) 0.06
a Coronary artery bypass graft.
b Percutaneous coronary intervention.
c Revascularization = CABG or PCI.
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This study found that people with schizophrenia appear to have less
severe coronary atherosclerosis than those without schizophrenia, but
signiﬁcantly highermortality.While there is a suggestion of a treatment
disparity to the extent that people with schizophrenia are not receiving
revascularization at the same rate as those without schizophrenia, our
survival analysis shows that the poor outcomes following catheteriza-
tion among those with schizophrenia cannot be explained by differ-
ences in anatomy or differences in revascularization patterns.
A central hypothesis of this study was that differences in coronary
revascularization rates among persons with and without schizophrenia
might reﬂect variation in underlying coronary anatomy. Our results do
suggest anatomical differences, such that persons with schizophrenia
presenting for catheterization did have less coronary atherosclerosis
and more importantly, less occlusive atherosclerosis. It has been
demonstrated that endothelial dysfunction plays a signiﬁcant role in
the development of CVD in the schizophrenia population. Ellingrod
et al. (2011) have shown that 50% of people with schizophrenia but
without CVD have evidence of signiﬁcant endothelial dysfunction as
measured by non-invasive peripheral arterial tonometry [18]. These de-
fects in vascular function were only partially explained by co-morbid
metabolic syndrome and conventional risk factors present in these pa-
tients. It remains to be elucidated whether schizophrenia increases
risk for CVD independent of traditional risk factors, but evidence does
suggest that it likely negatively modulates risk.
Another possibility is that symptoms of ischemia in patients with
schizophrenia are not related to occlusive atherosclerotic disease,
but related to arrhythmia; given that anti-psychotic medications
have been shown to have arrythmogenic potential. Recent data from
Murray-Thomas and colleagues (2013) have demonstrated that the
risk of arrhythmia and sudden cardiac death increased with anti-
psychotic dose and duration of anti-psychotic treatment [19]. The risk
of arrhythmia (prolonged QT syndrome in particular) can become
very high when other arrhythmogenic therapies are introduced, so dil-
igence to prevent harmful drug interactions is needed for patients with
severe mental illness treated with typical and atypical anti-psychotic
medications. We must also consider that the very high mortality
documented in our study population may be related to this previously
documented increase in the risk of sudden cardiac death associated
with anti-psychotic treatment [20]. However, it is unlikely that this isTable 4
Unadjusted and adjusted hazard ratios for death, schizophrenia vs no schizophrenia.
Crude HR (95% CI) p-Value Adjusteda HR (95% CI) p-Value
Full cohort 2.19 (1.68–2.85) b0.0001 1.85 (1.39–2.46) b0.0001
AMI only 2.25 (1.50–3.38) 0.0002 1.49 (0.90–2.47) 0.12
a Adjusted for demographic characteristics, co-morbidities, burden of coronary disease,
ejection fraction, and treatment received.the sole explanation for the mortality increase, as the odds of death
documented herein were nearly double themortality related to sudden
cardiac death reported in previous studies [21].
We also document a modest treatment disparity. People with
schizophrenia were signiﬁcantly more likely to be treated medically.
Due to limitations of our dataset, we could not determine the “appropri-
ateness” of the use of revascularization in any of our patients, but this
treatment difference persisted after adjusting for differences in coro-
nary anatomy. Some have suggested that this treatment disparity, and
lack of access to appropriate treatment of CVD more broadly, may be a
contributing factor to the premature mortality seen among those with
schizophrenia [22,23]. Our ﬁndings do not support this. Survival rates
were similar among people with schizophrenia who received medical0.0
0.2
0 3 6 9 12 15
Time from catheterization (years)
No schizophrenia Schizophrenia
Fig. 1.Panel A. KaplanMeier survival, full cohort (N= 1354). Panel B. Cox adjusted survival,
full cohort (N = 1354).
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Fig. 2. Panel A. KaplanMeier survival, AMI cohort N= 564. Panel B. Cox adjusted survival,
AMI cohort N = 564.
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very high mortality rate among people with schizophrenia, but this
was independent of severity of coronary anatomyormode of treatment.
The most notable ﬁnding of this study was the increase in mortality
among people with schizophrenia in the years following their catheteri-
zation. It is known that peoplewith severemental illness die 15–20 years
earlier than those without mental illness, with CVD and cancer being the
leading causes of prematuremortality in this population [24,25].While it
is widely acknowledged that medical care for people with severe mental
illness can be challenging and complex, the signiﬁcant mortality risk as-
sociated with these conditions is a fact that is likely under-appreciated
by many non-mental health care professionals. There is increasing inter-
est in the burden of preventablemedical deaths among thosewith severe
mental illness, particularly at a time when we have the best knowledge
on primary and secondary prevention of CVD. Strategies to enhance use
of these therapies to improve outcomes in people with mental illness
have been evaluated, and community treatment orders (CTOs) and
trans-disciplinary care have beenproven to increase CVD risk factorman-
agement and reduce mortality relative to usual care [14–16]. The results
of these studies identify that it is possible to improve CVD outcomes in
those with severemental illnesses. These strategies have been successful
because they likely increase medical treatment adherence. Around one-
third of outpatients with schizophrenia are non-adherent to their
medications at any given time during the course of their disease and up
to 75% of individuals with schizophrenia are non-adherent to their
medications within two years of discharge [26,27]. To improve health
outcomes in those with psychotic illness, treatment protocols need
to be geared toward improving patient adherence and surveying for
potentially harmful drug interactions [28].Amajor strength of this study is the use of a large, population-based
cardiac catheterization registry with clinically detailed data on all pa-
tients. We were able to control for several clinically relevant covariates
in our assessment of mortality including smoking status, and most im-
portantly, were able to account for differences in coronary anatomy.
This is the ﬁrst study to our knowledge to do so.
6. Study limitations
In our study, wewere able to account for comorbid disease, however,
not for severity of comorbid illness. Perhaps a greater limitation is not
being able to report on cause-speciﬁc mortality for all patients. While
we can report on a signiﬁcant increase in mortality in our schizophrenia
cohort, the speciﬁc causes for this mortality increase remain unclear.
Further, our inability to examine medication use and/or adherence
after discharge from hospital post-cardiac catheterization limits our
ability to explore important mechanisms for the documented mortality
increase among patients with schizophrenia.
7. Conclusions
In this cohort of individuals who underwent cardiac catheterization,
after adjusting for important clinical factors, we found that people with
schizophrenia are less likely to receive revascularization and have a
signiﬁcantly higher mortality rate relative to their peers. The acute
medical admission for the person with schizophrenia should be seen
as an opportunity to optimize care in these very vulnerable persons.
Care planning must involve mental health professionals, pharmacists
and possibly the use of mandated treatment to ensure ongoing care to
reduce mortality risk.
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